Roots Analysis is pleased to announce the publication of its recent study, titled, Global CAR-T Cell Therapy Market (4th Edition), 2022-2035.
The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:
A detailed assessment of the current market landscape of CAR-T-cell therapies.
An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors.
A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies.
An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies.
Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above).
An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies.
An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies.
An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022.
A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies.
Elaborate profiles of the several leading players in the domain of CAR-T cell therapies.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
Target Indication(s)
Non-Hodgkins Lymphoma
Multiple Myeloma
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Hodgkins Lymphoma
Acute Myeloid Leukemia
Ovarian Cancer
Generalized Myasthenia Gravis (MG)
Renal Cell Carcinoma
Target Antigen
CD19
BCMA
CD19/22
Others
Key Geographical Regions
North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
Miguel Forte (Chief Operating Officer, TxCell)
Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
Aino Kalervo (Former Competitive Intelligence Manager, Strategy Business Development, Theravectys)
Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players.
Autolus
bluebird Bio
Bristol Myers Squibb
Carsgen Therapeutics
Cellectis
Cellular Biomedicine Group
Gilead Sciences
Innovative Cellular Therapeutics
Kuur Therapeutics
Noile-Immune Biotech
Novartis
Shanghai GeneChem
Sinobioway Cell Therapy
Takara Bio
Wellington Zhaotai Therapies
Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
You may also be interested in the following titles:
Quantum Computing in Drug Discovery Services Market
You may also like to learn what our experts are sharing in Roots educational series:
mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule |
About Roots Analysis
Roots Analysisis a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
